# Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02509052** · PHASE1,PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leflunomide
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02509052
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-02
- **Primary completion:** 2018-09-18
- **Final completion:** 2022-06-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509052, "Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02509052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*